First Tracks Biotherapeutics Inc
TRAXHealthcare|Biotechnology|US
$47.90
+2.47 (+5.44%)
DCF Value
$6.37
Tangible Book / Share
$4.22
Cash / Share
$4.35
About
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Stock Price
+152.1%(1Y)
1M
+49.6%
3M
+5.7%
6M
+145.1%
YTD
+152.1%
1Y
+152.1%
3Y
+152.1%
5Y
+152.1%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$2.01B
Employees104
CEODaniel R. Faga
IPO DateApr 20, 2026
Beta3.37
52-Week Range$14.72 – $50.17
Avg Volume861,145
ExchangeNASDAQ
Websitefirsttracksbio.com
Ownership
Float85.3%
Shares Outstanding42.0M
Recent Insider Trades
Tamboli AjimAWARD
Nov 1, 202642,500 shares
Faga DanielAWARD
Nov 1, 2026136,000 shares
STONE BENJAMINAWARD
Nov 1, 202642,500 shares
Lizzul Paul F.AWARD
Nov 1, 202642,500 shares
Orwin John AOPTION EX.
Sep 15, 20261,300 shares
Peers
Recent News
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
Nov 3, 2026 · globenewswire.com
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 3, 2026 · globenewswire.com
First Tracks Biotherapeutics Announces $200 Million Private Placement
Oct 15, 2026 · globenewswire.com
First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor
Oct 14, 2026 · seekingalpha.com
First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals
Oct 13, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:37 AM